{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:18:02Z","timestamp":1791728282698,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T00:00:00Z","timestamp":1381968000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2013.387","type":"journal-article","created":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T14:18:41Z","timestamp":1382019521000},"page":"e862-e862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG"],"prefix":"10.1038","volume":"4","author":[{"given":"S","family":"Valdeolivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Pazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Bisogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Piscitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F A","family":"Iannotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Allar\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Sagredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Di Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,17]]},"reference":[{"key":"BFcddis2013387_CR1","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2174\/138161208785740108","volume":"14","author":"MR Pazos","year":"2008","unstructured":"Pazos MR, Sagredo O, Fern\u00e1ndez-Ruiz J . The endocannabinoid system in Huntington's disease. Curr Pharm Des 2008; 14: 2317\u20132325.","journal-title":"Curr Pharm Des"},{"key":"BFcddis2013387_CR2","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1476-5381.2011.01365.x","volume":"163","author":"J Fern\u00e1ndez-Ruiz","year":"2011","unstructured":"Fern\u00e1ndez-Ruiz J, Moreno-Martet M, Rodr\u00edguez-Cueto C, Palomo-Garo C, G\u00f3mez-Ca\u00f1as M, Valdeolivas S et al. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011; 163: 1365\u20131378.","journal-title":"Br J Pharmacol"},{"key":"BFcddis2013387_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/157488912798842278","volume":"7","author":"O Sagredo","year":"2012","unstructured":"Sagredo O, Pazos MR, Valdeolivas S, Fern\u00e1ndez-Ruiz J . Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Pat CNS Drug Discov 2012; 7: 41\u201348.","journal-title":"Recent Pat CNS Drug Discov"},{"key":"BFcddis2013387_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO . Huntington's disease. Lancet 2007; 369: 218\u2013228.","journal-title":"Lancet"},{"key":"BFcddis2013387_CR5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M . Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6: 919\u2013930.","journal-title":"Nat Rev Neurosci"},{"key":"BFcddis2013387_CR6","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/S0166-2236(00)01997-4","volume":"24","author":"CT McMurray","year":"2001","unstructured":"McMurray CT . Huntington\u2019s disease: new hope for therapeutics. Trends Neurosci 2001; 24: S32\u2013S38.","journal-title":"Trends Neurosci"},{"key":"BFcddis2013387_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/156652407781695738","volume":"7","author":"BL Wright","year":"2007","unstructured":"Wright BL, Barker RA . Established and emerging therapies for Huntington's disease. Curr Mol Med 2007; 7: 579\u2013587.","journal-title":"Curr Mol Med"},{"key":"BFcddis2013387_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2047-9158-2-2","volume":"2","author":"JM Burgunder","year":"2013","unstructured":"Burgunder JM . Translational research in Huntington's disease: opening up for disease modifying treatment. Transl Neurodegener 2013; 2: 2.","journal-title":"Transl Neurodegener"},{"key":"BFcddis2013387_CR9","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1097\/00001756-200410250-00015","volume":"15","author":"I Lastres-Becker","year":"2004","unstructured":"Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fern\u00e1ndez-Ruiz J, Brouillet E . Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 2004; 15: 2375\u20132379.","journal-title":"Neuroreport"},{"key":"BFcddis2013387_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.neuropharm.2006.06.013","volume":"51","author":"A Pintor","year":"2006","unstructured":"Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006; 51: 1004\u20131012.","journal-title":"Neuropharmacology"},{"key":"BFcddis2013387_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/glia.20838","volume":"57","author":"O Sagredo","year":"2009","unstructured":"Sagredo O, Gonz\u00e1lez S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia 2009; 57: 1154\u20131167.","journal-title":"Glia"},{"key":"BFcddis2013387_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jnr.22682","volume":"89","author":"O Sagredo","year":"2011","unstructured":"Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fern\u00e1ndez-Ruiz J . Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res 2011; 89: 1509\u20131518.","journal-title":"J Neurosci Res"},{"key":"BFcddis2013387_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","volume":"26","author":"O Sagredo","year":"2007","unstructured":"Sagredo O, Ramos JA, Decio A, Mechoulam R, Fern\u00e1ndez-Ruiz J . Cannabidiol reduced the striatal atrophy caused by 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007; 26: 843\u2013851.","journal-title":"Eur J Neurosci"},{"key":"BFcddis2013387_CR14","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/brain\/awp239","volume":"132","author":"J Palazuelos","year":"2009","unstructured":"Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009; 132: 3152\u20133164.","journal-title":"Brain"},{"key":"BFcddis2013387_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/brain\/awq278","volume":"134","author":"C Bl\u00e1zquez","year":"2001","unstructured":"Bl\u00e1zquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2001; 134: 119\u2013136.","journal-title":"Brain"},{"key":"BFcddis2013387_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/cn200114w","volume":"3","author":"S Valdeolivas","year":"2012","unstructured":"Valdeolivas S, Satta V, Pertwee RG, Fern\u00e1ndez-Ruiz J, Sagredo O . Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 2012; 3: 400\u2013406.","journal-title":"ACS Chem Neurosci"},{"key":"BFcddis2013387_CR17","unstructured":"De Y\u00e9benes J Phase II-clinical trial on neuroprotection with cannabinoids in Huntington\u2019s disease (SAT-HD). EudraCT 2010-024227-24."},{"key":"BFcddis2013387_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.phrs.2007.09.002","volume":"56","author":"T Bisogno","year":"2007","unstructured":"Bisogno T, Di Marzo V . Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacol Res 2007; 56: 428\u2013442.","journal-title":"Pharmacol Res"},{"key":"BFcddis2013387_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.neuint.2007.06.031","volume":"52","author":"T Bisogno","year":"2008","unstructured":"Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V . Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6\/2 mice, a transgenic model of Huntington's disease. Neurochem Int 2008; 52: 307\u2013313.","journal-title":"Neurochem Int"},{"key":"BFcddis2013387_CR20","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1097\/00001756-200107200-00017","volume":"12","author":"I Lastres-Becker","year":"2001","unstructured":"Lastres-Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington\u2019s disease. Neuroreport 2001; 12: 2125\u20132129.","journal-title":"Neuroreport"},{"key":"BFcddis2013387_CR21","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1046\/j.1471-4159.2003.01595.x","volume":"84","author":"I Lastres-Becker","year":"2003","unstructured":"Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fern\u00e1ndez-Ruiz J . Compounds acting at the endocannabinoid and\/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem 2003; 84: 1097\u20131109.","journal-title":"J Neurochem"},{"key":"BFcddis2013387_CR22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/sj.bjp.0705662","volume":"141","author":"S Toulmond","year":"2004","unstructured":"Toulmond S, Tang K, Bureau Y, Ashdown H, Degen S, O'Donnell R et al. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br J Pharmacol 2004; 141: 689\u2013697.","journal-title":"Br J Pharmacol"},{"key":"BFcddis2013387_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/00001756-200305060-00007","volume":"14","author":"I Lastres-Becker","year":"2003","unstructured":"Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fern\u00e1ndez-Ruiz J . Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 2003; 14: 813\u2013816.","journal-title":"Neuroreport"},{"key":"BFcddis2013387_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1083\/jcb.200305129","volume":"163","author":"T Bisogno","year":"2003","unstructured":"Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 2003; 163: 463\u2013468.","journal-title":"J Cell Biol"},{"key":"BFcddis2013387_CR25","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/j.1471-4159.2007.04668.x","volume":"102","author":"N Sang","year":"2007","unstructured":"Sang N, Zhang J, Chen C . COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J Neurochem 2007; 102: 1966\u20131977.","journal-title":"J Neurochem"},{"key":"BFcddis2013387_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1006\/exnr.1993.1213","volume":"124","author":"M Giordano","year":"1993","unstructured":"Giordano M, Takashima H, Herranz A, Poltorak M, Geller HM, Marone M et al. Immortalized GABAergic cell lines derived from rat striatum using a temperature-sensitive allele of the SV40 large T antigen. Exp Neurol 1993; 124: 395\u2013400.","journal-title":"Exp Neurol"},{"key":"BFcddis2013387_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.bbalip.2005.12.009","volume":"1761","author":"T Bisogno","year":"2006","unstructured":"Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 2006; 1761: 205\u2013212.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis2013387_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12035-007-8008-6","volume":"36","author":"R Mechoulam","year":"2007","unstructured":"Mechoulam R, Shohami E . Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007; 36: 68\u201374.","journal-title":"Mol Neurobiol"},{"key":"BFcddis2013387_CR29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nn1715","volume":"9","author":"AE Cardona","year":"2006","unstructured":"Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9: 917\u2013924.","journal-title":"Nat Neurosci"},{"key":"BFcddis2013387_CR30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1042\/BST0351119","volume":"35","author":"GC Brown","year":"2007","unstructured":"Brown GC . Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem Soc Trans 2007; 35: 1119\u20131121.","journal-title":"Biochem Soc Trans"},{"key":"BFcddis2013387_CR31","doi-asserted-by":"publisher","first-page":"538141","DOI":"10.1155\/2008\/538141","volume":"2008","author":"PF Stahel","year":"2008","unstructured":"Stahel PF, Smith WR, Bruchis J, Rabb CH . Peroxisome proliferator-activated receptors: \u2018key\u2019 regulators of neuroinflammation after traumatic brain injury. PPAR Res 2008; 2008: 538141.","journal-title":"PPAR Res"},{"key":"BFcddis2013387_CR32","doi-asserted-by":"publisher","first-page":"6970","DOI":"10.1021\/jm800978m","volume":"51","author":"G Ortar","year":"2008","unstructured":"Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V . Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem 2008; 51: 6970\u20136979.","journal-title":"J Med Chem"},{"key":"BFcddis2013387_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nchembio.129","volume":"5","author":"JZ Long","year":"2009","unstructured":"Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009; 5: 37\u201344.","journal-title":"Nat Chem Biol"},{"key":"BFcddis2013387_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1126\/science.1209200","volume":"334","author":"DK Nomura","year":"2011","unstructured":"Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011; 334: 809\u2013813.","journal-title":"Science"},{"key":"BFcddis2013387_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.celrep.2012.05.001","volume":"1","author":"JR Piro","year":"2012","unstructured":"Piro JR, Benjamin DI, Duerr JM, Pi Y, Gonzales C, Wood KM et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep 2012; 1: 617\u2013623.","journal-title":"Cell Rep"},{"key":"BFcddis2013387_CR36","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/jnen\/63.9.901","volume":"63","author":"L Minghetti","year":"2004","unstructured":"Minghetti L . Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901\u2013910.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFcddis2013387_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2174\/1568010054022051","volume":"4","author":"SF Tzeng","year":"2005","unstructured":"Tzeng SF, Hsiao HY, Mak OT . Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy 2005; 4: 335\u2013340.","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"BFcddis2013387_CR38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.2174\/138161208784480144","volume":"14","author":"H Yang","year":"2008","unstructured":"Yang H, Chen C . Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des 2008; 14: 1443\u20131451.","journal-title":"Curr Pharm Des"},{"key":"BFcddis2013387_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pharmthera.2008.08.001","volume":"120","author":"DF Woodward","year":"2008","unstructured":"Woodward DF, Carling RW, Cornell CL, Fliri HG, Martos JL, Pettit SN et al. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther 2008; 120: 71\u201380.","journal-title":"Pharmacol Ther"},{"key":"BFcddis2013387_CR40","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/bjp.2008.33","volume":"153","author":"SS Hu","year":"2008","unstructured":"Hu SS, Bradshaw HB, Chen JS, Tan B, Walker JM . Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br J Pharmacol 2008; 153: 1538\u20131549.","journal-title":"Br J Pharmacol"},{"key":"BFcddis2013387_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/1381612043453081","volume":"10","author":"KR Kozak","year":"2004","unstructured":"Kozak KR, Prusakiewicz JJ, Marnett LJ . Oxidative metabolism of endocannabinoids by COX-2. Curr Pharm Des 2004; 10: 659\u2013667.","journal-title":"Curr Pharm Des"},{"key":"BFcddis2013387_CR42","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/glia.20756","volume":"57","author":"S Kreutz","year":"2009","unstructured":"Kreutz S, Koch M, B\u00f6ttger C, Ghadban C, Korf HW, Dehghani F . 2-Arachidonoyl-glycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. Glia 2009; 57: 286\u2013294.","journal-title":"Glia"},{"key":"BFcddis2013387_CR43","doi-asserted-by":"publisher","first-page":"23513","DOI":"10.1155\/2007\/23513","volume":"2007","author":"Y Sun","year":"2007","unstructured":"Sun Y, Bennett A . Cannabinoids: a new group of agonists of PPARs. PPAR Res 2007; 2007: 23513.","journal-title":"PPAR Res"},{"key":"BFcddis2013387_CR44","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/35097089","volume":"413","author":"D Panikashvili","year":"2001","unstructured":"Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527\u2013531.","journal-title":"Nature"},{"key":"BFcddis2013387_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.imbio.2009.09.007","volume":"215","author":"SE O'Sullivan","year":"2010","unstructured":"O'Sullivan SE, Kendall DA . Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010; 215: 611\u2013616.","journal-title":"Immunobiology"},{"key":"BFcddis2013387_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/nen.0b013e3180517477","volume":"66","author":"L Minghetti","year":"2007","unstructured":"Minghetti L, Greco A, Potenza RL, Pezzola A, Blum D, Bantubungi K et al. Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. J Neuropathol Exp Neurol 2007; 66: 363\u2013371.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFcddis2013387_CR47","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1073\/pnas.0837397100","volume":"100","author":"P Teismann","year":"2003","unstructured":"Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003; 100: 5473\u20135478.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2013387_CR48","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.2174\/138161208784480171","volume":"14","author":"JJ Hoozemans","year":"2008","unstructured":"Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 2008; 14: 1419\u20131427.","journal-title":"Curr Pharm Des"},{"key":"BFcddis2013387_CR49","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1227\/01.NEU.0000154060.14900.8F","volume":"56","author":"JJ Gopez","year":"2005","unstructured":"Gopez JJ, Yue H, Vasudevan R, Malik AS, Fogelsanger LN, Lewis S et al. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 2005; 56: 590\u2013604.","journal-title":"Neurosurgery"},{"key":"BFcddis2013387_CR50","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.tips.2006.04.003","volume":"27","author":"QJ Wang","year":"2006","unstructured":"Wang QJ . PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci 2006; 27: 317\u2013323.","journal-title":"Trends Pharmacol Sci"},{"key":"BFcddis2013387_CR51","doi-asserted-by":"publisher","first-page":"22601","DOI":"10.1074\/jbc.M800524200","volume":"283","author":"J Zhang","year":"2008","unstructured":"Zhang J, Chen C . Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 2008; 283: 22601\u201322611.","journal-title":"J Biol Chem"},{"key":"BFcddis2013387_CR52","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/j.1476-5381.2011.01444.x","volume":"163","author":"H Du","year":"2001","unstructured":"Du H, Chen X, Zhang J, Chen C . Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-\u03b3. Br J Pharmacol 2001; 163: 1533\u20131549.","journal-title":"Br J Pharmacol"},{"key":"BFcddis2013387_CR53","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"WA Devane","year":"1992","unstructured":"Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946\u20131949.","journal-title":"Science"},{"key":"BFcddis2013387_CR54","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1042\/bj3220671","volume":"322","author":"T Bisogno","year":"1997","unstructured":"Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V . Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 1997; 322: 671\u2013677.","journal-title":"Biochem J"},{"key":"BFcddis2013387_CR55","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature00839","volume":"418","author":"G Marsicano","year":"2002","unstructured":"Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530\u2013534.","journal-title":"Nature"},{"key":"BFcddis2013387_CR56","doi-asserted-by":"publisher","first-page":"e31111","DOI":"10.1371\/journal.pone.0031111","volume":"7","author":"L Gatta","year":"2012","unstructured":"Gatta L, Piscitelli F, Giordano C, Boccella S, Lichtman A, Maione S et al. Discovery of prostamide F2\u03b1 and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. PLoS One 2012; 7: e31111.","journal-title":"PLoS One"},{"key":"BFcddis2013387_CR57","volume-title":"Maps and Guide to Microdissection of the Rat Brain","author":"M Palkovits","year":"1988","unstructured":"Palkovits M, Brownstein J . Maps and Guide to Microdissection of the Rat Brain. Elsevier: New York-Amsterdam-London, 1988."},{"key":"BFcddis2013387_CR58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ . Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265\u2013275.","journal-title":"J Biol Chem"},{"key":"BFcddis2013387_CR59","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","volume":"14","author":"JL Blankman","year":"2007","unstructured":"Blankman JL, Simon GM, Cravatt BF . A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007; 14: 1347\u20131356.","journal-title":"Chem Biol"}],"container-title":["Cell Death & Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cddis2013387.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cddis2013387","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2013387.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:53:40Z","timestamp":1672962820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2013387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,17]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10]]}},"alternative-id":["BFcddis2013387"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2013.387","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,17]]},"assertion":[{"value":"6 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}